NAGE logo

Niagen Bioscience, Inc. Stock Price

NasdaqCM:NAGE Community·US$542.2m Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 38 Fair Values set on narratives written by author

NAGE Share Price Performance

US$6.77
-0.79 (-10.45%)
US$16.04
Fair Value
US$6.77
-0.79 (-10.45%)
57.8% undervalued intrinsic discount
US$16.04
Fair Value
Price US$6.77
AnalystConsensusTarget US$16.04

NAGE Community Narratives

AnalystConsensusTarget·
Fair Value US$16.04 57.8% undervalued intrinsic discount

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

2users have liked this narrative
1users have commented on this narrative
18users have followed this narrative

Trending Discussion

Updated Narratives

NAGE logo

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

Fair Value: US$16.04 57.8% undervalued intrinsic discount
18 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Outstanding track record with flawless balance sheet.

0 Risks
3 Rewards

Niagen Bioscience, Inc. Key Details

US$124.7m

Revenue

US$45.0m

Cost of Revenue

US$79.7m

Gross Profit

US$59.3m

Other Expenses

US$20.4m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.26
63.89%
16.38%
0%
View Full Analysis

About NAGE

Founded
1999
Employees
104
CEO
Robert Fried
WebsiteView website
www.niagenbioscience.com

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Recent NAGE News & Updates

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Nov 15

Recent updates

No updates